Titan Pharmaceuticals Inc
NASDAQ:TTNP
Net Margin
Titan Pharmaceuticals Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Titan Pharmaceuticals Inc
NASDAQ:TTNP
|
6.5m USD | N/A | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
667.9B USD |
26%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
430.2B USD |
25%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
208.7B CHF |
14%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
185.7B GBP |
15%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
198.2B CHF |
25%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.5T DKK |
36%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
213B USD |
26%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.4B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
144.3B USD |
17%
|
Titan Pharmaceuticals Inc
Glance View
Titan Pharmaceuticals, Inc. engages in development of therapeutics for the treatment of chronic diseases utilizing its long-term, continuous drug delivery platform, ProNeura. The company is headquartered in South San Francisco, California and currently employs 11 full-time employees. The firm is engaged in developing therapeutics using its long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. Its ProNeura continuous drug delivery system consists of a small, solid rod-shaped implant made from a mixture of ethylene-vinyl acetate (EVA), and a drug substance. Its product Probuphine (buprenorphine implant), is based on ProNeura technology, which is used for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 milligrams (mg) or less a day of oral buprenorphine. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant and Nalmefene Implant. Its TP-2021 is used for the treatment of moderate-to-severe chronic pruritus. Its Nalmefene Implant is used for the prevention of relapse in opioid use disorder (OUD) patients following detoxification from opioids.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Titan Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of 0%.
You don't have any saved screeners yet